Drug distributor McKesson raised its fiscal 2026 profit forecast, focusing on oncology and specialty drug distribution. Shares rose 2% in extended trading. McKesson expects adjusted earnings per share of $38.35 to $38.85, beating analysts’ estimates. The U.S. pharmaceutical unit recorded sales of $86.5 billion, missing expectations. The company plans to invest in high-margin businesses like cancer medicines for growth.

Read more at Yahoo Finance: McKesson raises annual profit forecast on robust demand for specialty drugs